Table 6 Effects of δ-tocotrienol treatment on "Regulator Effects" section (70) of IPA analysis of "Diseases and Functions" in hepatitis C patients
ID | Consistency | Node | Regulator | Regulators | Target | Disease & | Diseases & Functions | Known Regulator-Disease/ |
|---|---|---|---|---|---|---|---|---|
Score | Total | Total | Total | Fuunctions Totals | Function Relationship | |||
1 | 36.338 | 57 | 9 | Ap1,CAMP,EIF2AK2,IL17A,IL1R,miR-155-5,STAT2 | 38 | 10 | activation of phagocytes | 48% (43/90) |
2 | 32.199 | 69 | 13 | 26s Proteasome,ANGPT2,Ap1,BCL2,CAMP,CEBPA,TGFA | 45 | 11 | activation of antigen presenting cells | 40% (57/143) |
3 | 30.414 | 57 | 12 | 26s Proteasome,CAMP,CSF1,F2RL1,IL17A,miR-21-5p,TGFA | 37 | 8 | activation of myeloid cells | 32% (31/96) |
4 | 30.375 | 97 | 13 | Ap1,CAMP,CCL5,EIF2AK2,F2RL1,FGF10,IL17A, | 64 | 20 | accumulation of l cells,leukopoiesis | 38% (99/260) |
5 | 28.605 | 56 | 10 | 26s Proteasome,BCL2,CAMP,STAT3,TGFA,TGM2 | 37 | 9 | adhesion of blood cells | 36% (32/90) |
6 | 25.456 | 49 | 8 | 26s Proteasome,F2RL1,IL1RN,IRF4,KLF3,STAT3,TGFA, | 32 | 9 | adhesion of immune cells | 26% (19/72) |
7 | 25.126 | 127 | 20 | ANGPT2,Ap1,CAMP,CST5,ETS1,F2RL1,IFNL1,IGF1,IL17A, | 92 | 15 | cell movement of granulocytes | 40% (121/300) |
8 | 24.82 | 53 | 8 | 26s Proteasome,BCL2,CSF1,F2RL1,IL1RN,STAT3,TGFA, | 38 | 7 | adhesion of blood cells | 41% (23/56) |
9 | 23.333 | 50 | 7 | CAMP,F2RL1,IL17A,mir-10,NRG1,TGFA,Tlr | 36 | 7 | cell viability of tumor cell lines | 63% (31/49) |
10 | 23.026 | 36 | 7 | 26s Proteasome,BCL2,CREB1,F2RL1,IFNA2,IL1RN,TGFA | 22 | 7 | binding of leukocytes | 24% (12/49) |
11 | 22.687 | 55 | 11 | 26s Proteasome,Calcineurin protein(s),CD38,EIF4E,F2RL1, | 37 | 7 | migration of macrophages | 23% (18/77) |
12 | 21.651 | 23 | 5 | CIITA,EBI3,IL27,PARP9,PDCD1 | 12 | 6 | activation of lymphatic system cells | 53% (16/30) |
13 | 21.355 | 41 | 6 | F2RL1,IL1RN,miR-155-5p (miRNAs w/seed UAAUGCU), | 28 | 7 | cell viability of mononuclear leukocytes | 36% (15/42) |
14 | 20.788 | 42 | 5 | F2RL1,IL1RN,Pkc(s),TNFSF11,VEGFA | 28 | 9 | adhesion of immune cells | 47% (21/45) |
15 | 20.715 | 50 | 7 | BTNL2,CIITA,Ifn,Ifnar,IL27,SYVN1,TGM2 | 33 | 10 | activation of leukocytes | 20% (14/70) |
16 | 19.856 | 54 | 8 | Ap1,CAMP,CSF2,EIF2AK2,F2RL1,IL1RN,miR-155-5p | 39 | 7 | chemotaxis of granulocytes | 38% (21/56) |
17 | 19.73 | 30 | 3 | CAMP,miR-155-5p (miRNAs w/seed UAAUGCU),PSMD10 | 19 | 8 | cell death of connective tissue cells | 33% (8/24) |
18 | 19.1 | 50 | 8 | F2,F2RL1,IL17A,MIF,mir-1,PPRC1,REL,TGFA | 35 | 7 | cell viability of lymphatic system cells | 46% (26/56) |
19 | 18.764 | 67 | 13 | Ap1,BCR (complex),CAMP,CSF2,IL12 (complex),IL21,STAT1, | 48 | 6 | synthesis of reactive oxygen species | 41% (32/78) |
20 | 18.475 | 41 | 7 | F2RL1,IL17A,LDL,mir-1,PPRC1,REL,RELA | 27 | 7 | cell viability of mononuclear leukocytes | 39% (19/49) |
21 | 18.429 | 75 | 8 | CCL5,F2RL1,IL1RN,miR-155-5pPSMD10,STAT4,TGFA | 49 | 18 | apoptosis of fibroblast cell lines | 31% (45/144) |
22 | 17.098 | 34 | 6 | F2RL1,Igm,IL1RN,IL6,STAT3,VEGFA | 23 | 5 | binding of myeloid cells | 37% (11/30) |
23 | 16.585 | 33 | 7 | CEBPA,EGF,FLT3LG,IL17A,MIF,mir-1,REL | 21 | 5 | NK cell proliferation | 37% (13/35) |
24 | 16.44 | 50 | 7 | CAMP,F2RL1,IL17A,JUN,LDL,NRG1,TGFA | 37 | 6 | activation of antigen presenting cells, | 50% (21/42) |
25 | 15.167 | 50 | 7 | CAMP,ETS1,F2,F2RL1,IL17A,MIF,TGFA | 36 | 7 | accumulation of cells | 55% (27/49) |
26 | 14.732 | 52 | 8 | 26s Proteasome,CSF1,IFNG,IL17A,IRF4,LDL,RELA,TGFA | 39 | 5 | chemotaxis of kidney cell lines | 43% (17/40) |
27 | 14.467 | 47 | 5 | 26s Proteasome,AKT1,LDL,TGFA,TGM2 | 37 | 5 | cellular homeostasis | 48% (12/25) |
28 | 12.928 | 70 | 11 | 26s Proteasome,APP,CREB1,CSF1,IFNA2,IFNG,IL17A,TGFA | 54 | 5 | translation of mRNA | 44% (24/55) |
29 | 12.667 | 50 | 5 | CEBPA,F2RL1,IL1RN,TNFSF11,VEGFA | 36 | 9 | quantity of IgG,recruitment of cells | 31% (14/45) |
30 | 12.33 | 50 | 7 | CAMP,EIF2AK2,F2RL1,HRAS,IL17A,IL1RN,STAT2 | 37 | 6 | homing of neutrophils,recruitment of cells | 40% (17/42) |
31 | 12.221 | 76 | 6 | CD40LG,GAST,miR-155-5p,TNFSF11 | 63 | 7 | production of reactive oxygen species | 45% (19/42) |
32 | 11.939 | 32 | 6 | CAMP,ETS1,IL17A,KITLG,miR-155-5,miR-21-5p | 22 | 4 | infiltration by myeloid cells | 38% (9/24) |
33 | 11.839 | 34 | 4 | BTNL2,Hbb-b2,Ifnar,TRIM24 | 24 | 6 | diabetes mellitus,hypersensitive reaction | 8% (2/24) |
34 | 10.818 | 46 | 5 | CEBPA,EGF,FLT3LG,IL17A,MIF | 35 | 6 | cell viability of tumor cell lines | 43% (13/30) |
35 | 9.707 | 21 | 5 | F2,F2RL1,IL1RN,IL6,VEGFA | 13 | 3 | migration of antigen presenting cells | 60% (9/15) |
36 | 8.693 | 13 | 4 | CD3,F2RL1,IL1RN,VEGFA | 7 | 2 | binding of myeloid cells | 25% (2/8) |
37 | 8.521 | 22 | 5 | 26s Proteasome,FOXO3,IL18,Pkc(s),TNFSF11 | 15 | 2 | response of lymphatic system cells | 60% (6/10) |
38 | 8.01 | 74 | 8 | A2M,CD40LG,GAST,mir-17,miR-17-5p,other miRNAs | 58 | 8 | anemia,binding of tumor cell lines | 28% (18/64) |
39 | 7.649 | 36 | 5 | GAST,PARP9,PIK3R1,SOX4,TGFA | 26 | 5 | anemia,autophagy,organismal death | 16% (4/25) |
40 | 7.464 | 87 | 13 | CD40LG,EP300,ERG,Igm,IL7,miR-19b-3p,miR-291a-3 | 69 | 5 | cell death of fibroblast cell lines | 28% (18/65) |
41 | 7.181 | 14 | 6 | CSF2,EDN1,F2,IL1B,KITLG,SPI1 | 7 | 1 | migration of granulocytes | 33% (2/6) |
42 | 6.791 | 26 | 5 | EDN1,F2,PRKCA,TNFSF11,VEGFA | 17 | 4 | Nephritis,synthesis of eicosanoid | 40% (8/20) |
43 | 6.633 | 17 | 3 | IRF5,miR-155-5p (miRNAs w/seed UAAUGCU),PSMD10 | 11 | 3 | apoptosis of connective tissue cells | 0% (0/9) |
44 | 6.379 | 18 | 3 | ETS1,GFI1,PRL | 13 | 2 | quantity of hematopoietic progenitor cells | 100% (6/6) |
45 | 6.306 | 22 | 3 | miR-155-5p (miRNAs w/seed UAAUGCU),miR-21-5p | 17 | 2 | cell death of connective tissue cells | 17% (1/6) |
46 | 6.183 | 27 | 3 | CREB1,IFNA2,PDCD1 | 22 | 2 | activation of leukocytes | 67% (4/6) |
47 | 5.667 | 14 | 1 | GFI1 | 9 | 4 | HIV infection,proliferation of blood cells | 75% (3/4) |
48 | 5.345 | 19 | 1 | IL5 | 14 | 4 | inflammation of body cavity | 50% (2/4) |
49 | 5.292 | 34 | 4 | CAMP,CSF2,IFNG,IL12 (complex) | 28 | 2 | synthesis of leukotriene | 75% (6/8) |
50 | 4.907 | 17 | 3 | EGF,PRDM1,SMARCA4 | 12 | 2 | endocytosis,phagocytosis of cells | 17% (1/6) |
51 | 4.276 | 18 | 2 | GFI1,Pkc(s) | 14 | 2 | differentiation of mononuclear leukocytes | 50% (2/4) |
52 | 4.199 | 37 | 3 | IL2,IL21,IL4 | 30 | 4 | apoptosis of connective tissue cells | 42% (5/12) |
53 | 4.16 | 17 | 3 | CAMP,CSF1,Immunoglobulin | 13 | 1 | mobilization of Ca2+ | 67% (2/3) |
54 | 3.889 | 12 | 2 | mir-8,miR-92a-3p (and other miRNAs w/seed AUUGCAC) | 8 | 2 | cell cycle progression | 0% (0/4) |
55 | 3.13 | 8 | 1 | FOXO1 | 5 | 2 | hyperplasia of lymphoid organ, | 0% (0/2) |
56 | 3.024 | 11 | 3 | Igm,Interferon alpha,STAT1 | 7 | 1 | apoptosis of kidney cell lines | 0% (0/3) |
57 | 3 | 13 | 3 | CEBPA,IFN Beta,mir-223 | 9 | 1 | production of protein | 33% (1/3) |
58 | 2.236 | 8 | 1 | mir-223 | 5 | 2 | Bacterial Infections,production of protein | 0% (0/2) |
59 | 1.789 | 7 | 1 | E2F1 | 5 | 1 | cell death of fibroblasts | 100% (1/1) |
60 | 1.789 | 7 | 1 | IL15 | 5 | 1 | cytotoxicity of natural killer cells | 100% (1/1) |
61 | 1.789 | 7 | 1 | IL1B | 5 | 1 | binding of lymphatic system cells | 100% (1/1) |
62 | 1.732 | 5 | 1 | CD28 | 3 | 1 | hyperplasia of lymphoid organ | 0% (0/1) |
63 | 1.508 | 13 | 1 | TP53 | 11 | 1 | catabolism of protein | 100% (1/1) |
64 | 0.802 | 17 | 2 | HRAS,TCR | 14 | 1 | expression of mRNA | 0% (0/2) |
65 | 0.577 | 32 | 4 | IFNA2,IRF7,TGFB1,TNF | 27 | 1 | systemic lupus erythematosus | 25% (1/4) |
66 | -2.714 | 13 | 1 | IL4 | 11 | 1 | infection of cells | 100% (1/1) |
67 | -4.082 | 8 | 1 | miR-21-5p (and other miRNAs w/seed AGCUUAU) | 6 | 1 | cell death | 100% (1/1) |
68 | -6.5 | 6 | 1 | TCF7L2 | 4 | 1 | apoptosis of fibroblast cell lines | 0% (0/1) |
69 | -16.743 | 5 | 1 | TRAP1 | 3 | 1 | synthesis of reactive oxygen species | 100% (1/1) |
70 | -23.519 | 58 | 1 | APP | 56 | 1 | cancer | 100% (1/1) |